Literature DB >> 9131756

Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP).

E Brittain1, J Palensky, J Blood, J Wittes.   

Abstract

Because many randomized clinical trials study more than one important outcome variable, evaluation of efficacy is often difficult and not completely satisfactory. This paper considers the use of a procedure for endpoint determination described by Follmann et al., that allows raters to integrate subjectively all relevant information about an individual's clinical course into a single univariate assessment. To explore the method's feasibility, we tested the procedure with data from a completed clinical trial, the Systolic Hypertension in the Elderly Program (SHEP). We provided raters blinded to treatment assignment with cards that schematically represent the clinical trajectories of SHEP study participants. The raters independently ranked these trajectories. The method combined ranks across raters to determine a single rank for each study participant; we used a rank procedure to test treatment effect. The major findings were: (i) the raters showed a high level of concordance of rankings; (ii) tests of treatment effect were highly statistically significant; (iii) three statistical methods were effective for implementing the ranking in the large study size case. These methods were use of: (a) scoring rules; (b) incomplete block designs, and (c) categorical ranking.

Entities:  

Mesh:

Year:  1997        PMID: 9131756     DOI: 10.1002/(sici)1097-0258(19970330)16:6<681::aid-sim487>3.0.co;2-h

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.

Authors:  Roland A Matsouaka; Rebecca A Betensky
Journal:  Stat Med       Date:  2014-11-13       Impact factor: 2.373

2.  A hierarchical rank test for crossover trials with censored data.

Authors:  Erica Brittain; Dean Follmann
Journal:  Stat Med       Date:  2011-12-05       Impact factor: 2.373

3.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

4.  Rethinking composite end points in clinical trials: insights from patients and trialists.

Authors:  Joshua M Stolker; John A Spertus; David J Cohen; Philip G Jones; Kaushik K Jain; Emily Bamberger; Brady B Lonergan; Paul S Chan
Journal:  Circulation       Date:  2014-09-08       Impact factor: 29.690

Review 5.  Pharmacotherapy for mild hypertension.

Authors:  Diana Diao; James M Wright; David K Cundiff; Francois Gueyffier
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

6.  Pharmacotherapy for hypertension in adults 60 years or older.

Authors:  Vijaya M Musini; Aaron M Tejani; Ken Bassett; Lorri Puil; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

Review 7.  First-line drugs for hypertension.

Authors:  James M Wright; Vijaya M Musini; Rupam Gill
Journal:  Cochrane Database Syst Rev       Date:  2018-04-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.